These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27890661)

  • 1. Studying brain-regulation of immunity with optogenetics and chemogenetics; A new experimental platform.
    Ben-Shaanan T; Schiller M; Rolls A
    Brain Behav Immun; 2017 Oct; 65():1-8. PubMed ID: 27890661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optogenetics and Chemogenetics.
    Vlasov K; Van Dort CJ; Solt K
    Methods Enzymol; 2018; 603():181-196. PubMed ID: 29673525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Chemogenetics and Optogenetics to Dissect Brain-Immune Interactions.
    Korin B; Rolls A
    Methods Mol Biol; 2018; 1781():195-208. PubMed ID: 29705849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of DREADDs to Deconstruct Behavior.
    Whissell PD; Tohyama S; Martin LJ
    Front Genet; 2016; 7():70. PubMed ID: 27242888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.
    Burnett CJ; Krashes MJ
    J Neurosci; 2016 Sep; 36(36):9268-82. PubMed ID: 27605603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates.
    Galvan A; Caiola MJ; Albaugh DL
    J Neural Transm (Vienna); 2018 Mar; 125(3):547-563. PubMed ID: 28238201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
    Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
    ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.
    Campbell EJ; Marchant NJ
    Br J Pharmacol; 2018 Apr; 175(7):994-1003. PubMed ID: 29338070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemogenetic modulation of astrocytes and microglia: State-of-the-art and implications in neuroscience.
    Bossuyt J; Van Den Herrewegen Y; Nestor L; Buckinx A; De Bundel D; Smolders I
    Glia; 2023 Sep; 71(9):2071-2095. PubMed ID: 37222453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemogenetic Signaling in Space and Time: Considerations for Designing Neuroscience Experiments Using DREADDs.
    Clark PJ; Brodnik ZD; España RA
    Neuroscientist; 2024 Jun; 30(3):328-346. PubMed ID: 36408535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemogenetic and Optogenetic Manipulations of Microglia in Chronic Pain.
    Parusel S; Yi MH; Hunt CL; Wu LJ
    Neurosci Bull; 2023 Mar; 39(3):368-378. PubMed ID: 35976535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating Dopamine Signaling and Behavior with Chemogenetics: Concepts, Progress, and Challenges.
    Runegaard AH; Fitzpatrick CM; Woldbye DPD; Andreasen JT; Sørensen AT; Gether U
    Pharmacol Rev; 2019 Apr; 71(2):123-156. PubMed ID: 30814274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laser Lights and Designer Drugs: New Techniques for Descending Levels of Mechanisms "in a Single Bound"?
    Bickle J
    Top Cogn Sci; 2020 Oct; 12(4):1241-1256. PubMed ID: 31489792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optogenetics and pharmacogenetics: principles and applications.
    Jiang J; Cui H; Rahmouni K
    Am J Physiol Regul Integr Comp Physiol; 2017 Dec; 313(6):R633-R645. PubMed ID: 28794102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral Vector Delivery of DREADDs for CNS Therapy.
    Pickering CA; Mazarakis ND
    Curr Gene Ther; 2021; 21(3):191-206. PubMed ID: 33573551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemogenetic manipulation of ventral pallidal neurons impairs acquisition of sign-tracking in rats.
    Chang SE; Todd TP; Bucci DJ; Smith KS
    Eur J Neurosci; 2015 Dec; 42(12):3105-16. PubMed ID: 26469930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in optogenetics and pharmacogenetics.
    Aston-Jones G; Deisseroth K
    Brain Res; 2013 May; 1511():1-5. PubMed ID: 23422677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How structure informs and transforms chemogenetics.
    Roth BL
    Curr Opin Struct Biol; 2019 Aug; 57():9-16. PubMed ID: 30818201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical Considerations for the Use of DREADD and Other Chemogenetic Receptors to Regulate Neuronal Activity in the Mammalian Brain.
    Aldrin-Kirk P; Björklund T
    Methods Mol Biol; 2019; 1937():59-87. PubMed ID: 30706390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Behavioral Manipulation via Orally Delivered Chemogenetic Actuator in Macaques.
    Oyama K; Hori Y; Nagai Y; Miyakawa N; Mimura K; Hirabayashi T; Inoue KI; Takada M; Higuchi M; Minamimoto T
    J Neurosci; 2022 Mar; 42(12):2552-2561. PubMed ID: 35110390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.